Background: Attention and working memory symptoms are among the most common late effects in survivors of pediatric brain tumors, and are often associated with academic and psychosocial difficulties. Diagnostic and treatment approaches derived from the literature on attention-deficit hyperactivity disorder (ADHD) have frequently been applied to survivors, yet the extent of overlap in cognitive profiles between these groups is unclear. The objective of the present study is to compare neurocognition in survivors of brain tumors and children with neurodevelopmental ADHD. Methods: Neuropsychological data were abstracted from clinically referred brain tumor survivors (n = 105, Mage = 12.0 y, 52.4% male) and children with ADHD (n = 178, Mage = 11.1 y, 64.0% male). Data consist of a battery of parent-report questionnaires and performance-based neuropsychological measures. Results: Twenty-five survivors (23.8%) of pediatric brain tumors met symptom criteria for ADHD. Participants with neurodevelopmental ADHD and survivors who met ADHD criteria had significantly greater parent- (P < 0.001) and teacher-reported (P < 0.001) working memory and behavior regulation difficulties than survivors of tumor who did not meet criteria. Children with ADHD symptoms also performed worse on measures of sustained attention than survivors without ADHD symptoms (P < 0.001). Additionally, survivors with ADHD symptoms had greater performance-based working memory difficulties than either survivors without attention problems or children with neurodevelopmental ADHD (P = 0.002). Conclusions: Nearly a quarter of survivors with attention symptoms have functional profiles that are similar to children with neurodevelopmental ADHD. They also experience more neurocognitive impairments than survivors without attentional difficulties, particularly in working memory. Screening for ADHD symptoms may help providers triage a subset of individuals in need of earlier or additional neuropsychological assessment.
Background: Attention and working memory symptoms are among the most common late effects in survivors of pediatric brain tumors, and are often associated with academic and psychosocial difficulties. Diagnostic and treatment approaches derived from the literature on attention-deficit hyperactivity disorder (ADHD) have frequently been applied to survivors, yet the extent of overlap in cognitive profiles between these groups is unclear. The objective of the present study is to compare neurocognition in survivors of brain tumors and children with neurodevelopmental ADHD. Methods: Neuropsychological data were abstracted from clinically referred brain tumor survivors (n = 105, Mage = 12.0 y, 52.4% male) and children with ADHD (n = 178, Mage = 11.1 y, 64.0% male). Data consist of a battery of parent-report questionnaires and performance-based neuropsychological measures. Results: Twenty-five survivors (23.8%) of pediatric brain tumors met symptom criteria for ADHD. Participants with neurodevelopmental ADHD and survivors who met ADHD criteria had significantly greater parent- (P < 0.001) and teacher-reported (P < 0.001) working memory and behavior regulation difficulties than survivors of tumor who did not meet criteria. Children with ADHD symptoms also performed worse on measures of sustained attention than survivors without ADHD symptoms (P < 0.001). Additionally, survivors with ADHD symptoms had greater performance-based working memory difficulties than either survivors without attention problems or children with neurodevelopmental ADHD (P = 0.002). Conclusions: Nearly a quarter of survivors with attention symptoms have functional profiles that are similar to children with neurodevelopmental ADHD. They also experience more neurocognitive impairments than survivors without attentional difficulties, particularly in working memory. Screening for ADHD symptoms may help providers triage a subset of individuals in need of earlier or additional neuropsychological assessment.
Authors: Kevin R Krull; Raja B Khan; Kirsten K Ness; Davonna Ledet; Liang Zhu; Ching-Hon Pui; Scott C Howard; Deo Kumar Srivastava; Noah D Sabin; Melissa M Hudson; E Brannon Morris Journal: Pediatr Blood Cancer Date: 2011-01-28 Impact factor: 3.167
Authors: Katherine T Baum; Stephanie K Powell; Lisa A Jacobson; Marsha N Gragert; Laura A Janzen; Iris Paltin; Celiane M Rey-Casserly; Greta N Wilkening Journal: Pediatr Blood Cancer Date: 2017-01-25 Impact factor: 3.167
Authors: Heather M Conklin; Jason M Ashford; Kellie N Clark; Karen Martin-Elbahesh; Kristina K Hardy; Thomas E Merchant; Robert J Ogg; Sima Jeha; Lu Huang; Hui Zhang Journal: J Pediatr Psychol Date: 2017-03-01
Authors: Katherine H Moyer; Victoria W Willard; Alan M Gross; Kelli L Netson; Jason M Ashford; Lisa S Kahalley; Shengjie Wu; Xiaoping Xiong; Heather M Conklin Journal: Pediatr Blood Cancer Date: 2012-07-27 Impact factor: 3.167
Authors: Wilburn E Reddick; Delaram J Taghipour; John O Glass; Jason Ashford; Xiaoping Xiong; Shengjie Wu; Melanie Bonner; Raja B Khan; Heather M Conklin Journal: Pediatr Blood Cancer Date: 2014-01-25 Impact factor: 3.167
Authors: Marvin So; Eric J Dziuban; Caitlin S Pedati; Joseph R Holbrook; Angelika H Claussen; Brenna O'Masta; Brion Maher; Audrey A Cerles; Zayan Mahmooth; Laurel MacMillan; Jennifer W Kaminski; Margaret Rush Journal: Prev Sci Date: 2022-08-10
Authors: Yuliang Wang; Anthony Pak Yin Liu; Tatia Mei-Chun Lee; Wilfred Hing Sang Wong; Daniel Yee Tak Fong; Lok Kan Leung; Matthew Ming Kong Shing; Dennis Tak-Loi Ku; Godfrey Chi-Fung Chan; Winnie Wan-Yee Tso Journal: Cancers (Basel) Date: 2022-07-04 Impact factor: 6.575